These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 19218306

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [Abstract] [Full Text] [Related]

  • 3. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
    Jones S, Stokoe C, Sborov M, Braun M, Ethirajan S, Kutteh L, Pippen J, Patel M, Paul D, Blum JL, Holmes FA, Myron MC, Cantrell J, Hartung NL, Look RM, Di Salle E, Davis JC, Ilegbodu D, Asmar L.
    Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y.
    Oncology; 2010 Dec; 79(5-6):376-81. PubMed ID: 21430407
    [Abstract] [Full Text] [Related]

  • 7. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
    Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S.
    Br J Cancer; 2006 Jul 17; 95(2):153-8. PubMed ID: 16835585
    [Abstract] [Full Text] [Related]

  • 10. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
    Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC, Kilburn LS.
    Breast Cancer Res Treat; 2010 Nov 17; 124(1):153-61. PubMed ID: 20730486
    [Abstract] [Full Text] [Related]

  • 11. Exemestane or tamoxifen?
    Ueda M, Toji E, Noda S.
    Lancet; 2007 May 12; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract] [Full Text] [Related]

  • 12. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
    Kalder M, Hans D, Kyvernitakis I, Lamy O, Bauer M, Hadji P.
    J Clin Densitom; 2014 May 12; 17(1):66-71. PubMed ID: 23562130
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
    Hadji P, Asmar L, van Nes JG, Menschik T, Hasenburg A, Kuck J, Nortier JW, van de Velde CJ, Jones SE, Ziller M.
    J Cancer Res Clin Oncol; 2011 Jun 12; 137(6):1015-25. PubMed ID: 21170551
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep 12; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 16. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.
    Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback DG.
    Climacteric; 2012 Oct 12; 15(5):460-6. PubMed ID: 22321061
    [Abstract] [Full Text] [Related]

  • 17. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.
    J Clin Oncol; 2010 Mar 10; 28(8):1294-300. PubMed ID: 20142601
    [Abstract] [Full Text] [Related]

  • 18. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
    Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A.
    Gynecol Oncol; 2010 Dec 10; 119(3):500-5. PubMed ID: 20832103
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Intergroup Exemestane Study.
    N Engl J Med; 2004 Mar 11; 350(11):1081-92. PubMed ID: 15014181
    [Abstract] [Full Text] [Related]

  • 20. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.
    Ned Tijdschr Geneeskd; 2006 Dec 30; 150(52):2863-9. PubMed ID: 17319217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.